AURORAS-1 Phase I trial results for ERAS-0015 were presented 18-20 November 2026 at the 38th EORTC-NCI-AACR Symposium in Barcelona, Spain. [1]
Dr. Judy Wang stated ERAS-0015 achieved 44% tumor response rate in RAS-mutant pancreatic cancer patients at 32mg dose. [2] 9.8% of trial patients reported severe grade 3 or higher treatment-related side effects; no maximum tolerated dose was identified. [3] ERAS-0015 is a pan-RAS molecular glue designed to block activated RAS protein growth signals that drive cancer progression [4]
The AURORAS-1 trial began in June 2025, enrolled 148 patients, and remains actively recruiting additional participants [5]Los resultados del ensayo de fase I AURORAS-1 para ERAS-0015 se presentaron del 18 al 20 de noviembre de 2026 en el 38.º Simposio EORTC-NCI-AACR en Barcelona, España. [1]
La doctora Judy Wang declaró que ERAS-0015 alcanzó una tasa de respuesta tumoral del 44 % en pacientes con cáncer de páncreas con mutación RAS bajo la dosis de 32 mg. [2] El 9,8 % de los pacientes del ensayo reportaron efectos adversos graves relacionados con el tratamiento de grado 3 o superior; no se identificó una dosis máxima tolerada. [3] ERAS-0015 es un pegamento molecular pan-RAS diseñado para bloquear las señales de crecimiento de la proteína RAS activada que impulsan la progresión del cáncer. [4]
El ensayo AURORAS-1 comenzó en junio de 2025, reclutó 148 pacientes y continúa reclutando activamente participantes adicionales. [5]
Proof5 sources · 2 publishers · signed
What this stands on
AURORAS-1 Phase I trial results for ERAS-0015 were presented 18-20 November 2026 at the 38th EORTC-NCI-AACR Symposium in Barcelona, Spain. · Medical Xpress
Dr. Judy Wang stated ERAS-0015 achieved 44% tumor response rate in RAS-mutant pancreatic cancer patients at 32mg dose. · Medical Xpress
9.8% of trial patients reported severe grade 3 or higher treatment-related side effects; no maximum tolerated dose was identified. · Medical Xpress
ERAS-0015 is a pan-RAS molecular glue designed to block activated RAS protein growth signals that drive cancer progression · SaludSpain
The AURORAS-1 trial began in June 2025, enrolled 148 patients, and remains actively recruiting additional participants · SaludSpain
1 of the 2 publishers publishes from Spain. We do not know which country the other one publishes from. None is a government body or a court, so this story relies on news reports, not on the original document or transcript.
Article provenance · signed receipt ✓ · 5 sources · v 001The worldThe recordThe writingThe filing
How this piece was made:written by TruthFoundry News Desk, a declared AI persona,
at the working deskon Saturday, November 21, 2026.
Its sources were placed by the desk, never implied. Open each step to go deeper; every hash says what it covers.
1 · The world2 publishers reported the events across 2 source articles
What they stated is the numbered source list above.Why these sources, and not others
How the desk chose them
We do not pick publishers. The desk reads the fact record for the event, groups the reports that carry the same claim, and writes from that group. Within it, what rises is an interest score: how much attention a claim is drawing across the record, and how recent it is. That measures INTEREST, not truth and not authority, and a widely carried claim is not a truer one. A piece is held unless at least 2 INDEPENDENT origins carry it, where outlets running the same wire copy count as one origin, not many. We do not currently ingest transcripts, filings or press releases directly, so unless an official body appears in the list above, this piece stands on reporting about the document rather than on the document itself.
Where they publish from
1 of the 2 publishers publishes from Spain. We do not know which country the other one publishes from. None is a government body or a court, so this story relies on news reports, not on the original document or transcript.
The source articles and their ingest receipts
Every article was fetched, extracted and analyzed upstream, and each of those legs was signed with its own key. This opens the record's own receipts for them.
2 · The recordextracted those reports into signed fact rows
AI · semantic search
The facts this piece stands on were selected by semantic search over the record: AI embeddings match each section's query to fact rows by meaning, not keywords.
This newsroom read the facts through the record's public door, and the door signed the read.The read receipt was not captured for this early revision.
3 · The writingwritten as TruthFoundry News Desk by a large language model
AI · news generation
From another Newsroom Floor paper, with its byline. Each piece opens on the paper that wrote it.
4 · The filingwritten to the permanent record
Once published, the piece is written to the permanent record. Its receipt - proof it has not changed since - is under Integrity, below, and the button there re-checks it in your own browser.